首页> 外文OA文献 >BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma : BYL719 PI3Kalpha inhibitor: therapeutic value in osteosarcoma

【2h】

BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma : BYL719 PI3Kalpha inhibitor: therapeutic value in osteosarcoma

机译：BYL719，一种新的α特异性pI3K抑制剂：单次给药并与常规化疗联合用于治疗骨肉瘤：BYL719 pI3Kalpha抑制剂：骨肉瘤的治疗价值

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

International audience

机译：国际观众

著录项

作者
Gobin, Bérengère; Huin, Marc Baud'; Lamoureux, François; Ory, Benjamin; Charrier, Céline; Lanel, Rachel; Battaglia, Séverine; Rédini, Françoise; Lézot, Frédéric; Blanchard, Frédéric; Heymann, Dominique;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. BYL719, a new alpha-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma [J] . Gobin Berengere, Huin Marc Baud, Lamoureux Francois, International Journal of Cancer =: Journal International du Cancer . 2015,第4期

机译：BYL719，一种新型的α-特异性PI3K抑制剂：单次给药并与常规化学疗法联合用于治疗骨肉瘤
2. BYL719, a new alpha-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma [J] . Gobin Berengere, Huin Marc Baud, Lamoureux Francois, International Journal of Cancer =: Journal International du Cancer . 2015,第4期

机译：BYL719，一种新型的α-特异性PI3K抑制剂：单次给药并与常规化学疗法联合用于治疗骨肉瘤
3. Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC) [J] . Chi Hang Wong, Brigette Buig Yue Ma, Hio Teng Cheong, American Journal of Cancer Research . 2015,第4期

机译：PI3K抑制剂BYL719作为单一药物的临床前评价及其与顺铂或MEK抑制剂联合在鼻咽癌（NPC）中的协同作用
4. PHASE I EVALUATION OF A CARBOPLATIN AND DOXORUBICIN COMBINATION CHEMOTHERAPY PROTOCOL FOR DOGS WITH OSTEOSARCOMA [C] . Jeffrey N Bryan, Kerry C Rissetto, Carolyn J Henry, Annual conference of the Veterinary Cancer Society . 2008

机译：患有骨肉瘤的犬犬的Carboplatin和多柔比星组合化疗方案的I级评估
5. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-Clinical Mechanistic Assessment [D] . Moorthy, Ganesh P. 2015

机译：BEZ235，PI3K / mTOR抑制剂和依维莫司，mTOR抑制剂的新型组合的临床药代动力学：I期临床研究和非临床机制评估
6. Preclinical evaluation of PI3K inhibitor BYL719 as a single agent and its synergism in combination with cisplatin or MEK inhibitor in nasopharyngeal carcinoma (NPC) [O] . Chi Hang Wong, Brigette Buig Yue Ma, Hio Teng Cheong, 2015

机译：PI3K抑制剂BYL719作为单一药物的临床前评价及其与顺铂或MEK抑制剂联合在鼻咽癌（NPC）中的协同作用
7. BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma : BYL719 PI3Kalpha inhibitor: therapeutic value in osteosarcoma [O] . Gobin, Bérengère, Huin, Marc Baud', Lamoureux, François, 2015

机译：BYL719，一种新的α特异性PI3K抑制剂：单一给药并与常规化疗结合治疗骨肉瘤：BYL719 PI3Kalpha抑制剂：在骨肉瘤中的治疗价值

BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma : BYL719 PI3Kalpha inhibitor: therapeutic value in osteosarcoma

摘要

著录项

相似文献

相关主题

期刊订阅